Drug shortage: Liraglutide Injection (LIRAGLUTIDE, SAXENDA, VICTOZA)
FDA lists 11 presentations as Current. Availability: Limited Availability (3), Available (6). Reason: Discontinuation of the manufacture of the drug; Delay in shipping of the drug. Companies: Meitheal Pharmaceuticals, Inc., Novo Nordisk, Inc., Teva Pharmaceuticals USA, Inc., Hikma Pharmaceuticals USA, Inc..
- Published by source
- 2023-07-18
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-23
Affected
- Manufacturer
- Meitheal Pharmaceuticals, Inc.
- Products
- Liraglutide Injection LIRAGLUTIDE SAXENDA VICTOZA
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: Current — Limited Availability
Remedy / actions:
- Product will be available until discontinuation in January 2027
- Estimated shortage duration: TBD
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2023-07-18
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #903 | new | 2026-10-22 | b158195b99af…2351e4 | 748f6514da15…9470a9 |
| #1151 | update | 2026-10-23 | 7f4df0729f2f…7f2792 | 41e4edd9257a…2ef1e7 |
| #1355 | update | 2026-10-23 | 9e54f1fa72e2…7093b9 | 1e463f7c3b58…baa8f7 |
Chain head: #1479 ad3417dbc128…777bd4